Hydroxyethylene sulfones as a new scaffold to address aspartic proteases:: Design, synthesis, and structural characterization

被引:13
作者
Specker, E
Böttcher, J
Heine, A
Sotriffer, CA
Lilie, H
Schoop, A
Müller, G
Griebenow, N
Klebe, G
机构
[1] Univ Marburg, Inst Pharmazeut Chem, D-35032 Marburg, Germany
[2] Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle Saale, Germany
[3] Boehringer Ingelheim, Vienna, Austria
[4] Axxima Pharmaceut AG, Munich, Germany
[5] Bayer AG, Elberfeld, Germany
关键词
D O I
10.1021/jm050224y
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Hydroxyethylene sulfones were developed as novel scaffolds against aspartyl proteases. A diastereoselective synthesis has been established to introduce the required side chain decoration with desired stereochemistry. Depending on the substitution of the hydroxyethylene-sulfone core, micro- to submicromolar inhibition of HIV-1 protease is achieved for the S-configuration at P, and R-configuration at the hydroxy-group-bearing backbone atom. This stereochemical preference is consistent with the S,R configuration of amprenavir. The racemic mixture of the most potent derivative (K-i = 80 nM) was separated by chiral HPLC, revealing the S,R,S-enantiomer to be more active (K-i = 45 nM). Docking studies suggested this isomer as the more active one. The subsequently determined crystal structure with HIV-1 protease, cocrystallized from a racemic mixture, exclusively reveals the S,R,S-enantiomer accommodated to the binding pocket. The transition state mimicking hydroxy group of the inhibitor is centered between both catalytic aspartates, while either its carbonyl or sulfonyl group forms H-bonds to the structurally conserved water mediating interactions between ligand and Ile50NH/Ile50NH' of both flaps. Biological testing of the stereoisomeric hydroxyethylene sulfones against cathepsin D and beta-secretase did not reveal significant inhibition. Most likely, the latter proteases require inverted configuration at the hydroxy group.
引用
收藏
页码:6607 / 6619
页数:13
相关论文
共 35 条
[1]   INHIBITION OF CATHEPSIN-D BY SUBSTRATE-ANALOGS CONTAINING STATINE AND BY ANALOGS OF PEPSTATIN [J].
AGARWAL, NS ;
RICH, DH .
JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (12) :2519-2524
[2]  
Anh N.T., 1980, TOP CURR CHEM, V88, P145
[3]   CRYSTAL-STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN-D - IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN [J].
BALDWIN, ET ;
BHAT, TN ;
GULNIK, S ;
HOSUR, MV ;
SOWDER, RC ;
CACHAU, RE ;
COLLINS, J ;
SILVA, AM ;
ERICKSON, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (14) :6796-6800
[4]   2′,6′-dimethylphenoxyacetyl:: A new achiral high affinity P3-P2 ligand for peptidomimetic-based HIV protease inhibitors [J].
Beaulieu, PL ;
Anderson, PC ;
Cameron, DR ;
Croteau, G ;
Gorys, V ;
Grand-Maitre, C ;
Lamarre, D ;
Liard, F ;
Paris, W ;
Plamondon, L ;
Soucy, F ;
Thibeault, D ;
Wernic, D ;
Yoakim, C ;
Pav, S ;
Tong, L .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (06) :1094-1108
[5]   RENIN INHIBITORS - DIPEPTIDE ANALOGS OF ANGIOTENSINOGEN INCORPORATING TRANSITION-STATE, NONPEPTIDIC REPLACEMENTS AT THE SCISSILE BOND [J].
BOLIS, G ;
FUNG, AKL ;
GREER, J ;
KLEINERT, HD ;
MARCOTTE, PA ;
PERUN, TJ ;
PLATTNER, JJ ;
STEIN, HH .
JOURNAL OF MEDICINAL CHEMISTRY, 1987, 30 (10) :1729-1737
[6]  
CHEREST M, 1968, TETRAHEDRON LETT, V18, P2205
[7]  
Darke P L, 1994, Adv Pharmacol, V25, P399, DOI 10.1016/S1054-3589(08)60438-X
[8]   Structure-based design:: Potent inhibitors of human brain memapsin 2 (β-secretase) [J].
Ghosh, AK ;
Bilcer, G ;
Harwood, C ;
Kawahama, R ;
Shin, D ;
Hussain, KA ;
Hong, L ;
Loy, JA ;
Nguyen, C ;
Koelsch, G ;
Ermolieff, J ;
Tang, J .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (18) :2865-2868
[9]   Knowledge-based scoring function to predict protein-ligand interactions [J].
Gohlke, H ;
Hendlich, M ;
Klebe, G .
JOURNAL OF MOLECULAR BIOLOGY, 2000, 295 (02) :337-356
[10]  
Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO